NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS

• US 20080279949A1
• Filed: 05/09/2008
• Published: 11/13/2008
• Est. Priority Date: 03/20/2002
• Status: Abandoned Application

• Current Assignee: Elan Pharma International Limited (Perrigo Company PLC)
• Original Assignee: Elan Pharma International Limited (Perrigo Company PLC)
• Inventors: Ryde, Tuula, Jain, Rajeev, Cary, Greta G., Bosch, H. William, Pruitt, John, Walters, Amy, MERISKO-LIVERSIDGE, Elaine
• Application Number:
  US12/117,982
• Publication Number:
  US 20080279949A1
• Time in Patent Office: Days
• US Class Current: 424/489
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/565 not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
• CPC Class Codes: A61K 9/145 with organic compounds
• CPC Class Codes: A61K 9/146 with organic macromolecular compounds
• CPC Class Codes: A61K 9/148 with compounds of unknown constitution, e.g. material from plants or animals with oils, fats, waxes, shellac A61K9/145
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/04 specific for metastasis
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system

Abstract

Nanoparticulate compositions comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.

Claims

1-86. -86. (canceled)

87. An angiogenesis inhibitor composition consisting of:

(a) particles of an angiogenesis inhibitor, wherein the angiogenesis inhibitor is paclitaxel or a salt thereof, having an effective average particle size of less than about 2000 nm; and

(b) associated with the surface thereof at least one surface stabilizer, wherein the surface stabilizer is essentially free of intermolecular cross linkages.

88. The composition of claim 87, wherein the angiogenesis inhibitor is selected from the group consisting of a crystalline phase, an amorphous phase, and a semi-crystalline phase.

89. The composition of claim 87, wherein the effective average particle size of the angiogenesis inhibitor is selected from the group consisting of less than about 1900 nm, less than about 1800 nm, less than about 1700 nm, less than about 1600 nm, less than about 1500 nm, less than about 1400 nm, less than about 1300 nm, less than about 1200 nm, less than about 1100 nm, less than about 1000 nm, less than about 900 mm, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 250 nm, less than about 200 nm, less than about 100 nm, less than about 75 nm, and less than about 50 nm.

90. The composition of claim 87, wherein the composition is formulated for administration selected from the group consisting of oral, pulmonary, rectal, opthalmic, colonic, parenteral, intracisternal, intravaginal, intraperitoneal, local, buccal, nasal, and topical administration.

91. The composition of claim 87, wherein the composition is formulated into a dosage form selected from the group consisting of liquid dispersions, gels, aerosols, ointments, creams, controlled release formulations, fast melt formulations, lyophilized formulations, tablets, capsules, delayed release formulations, extended release formulations, pulsatile release formulations, and mixed immediate release and controlled release formulations.

93. The composition of claim 87, wherein the angiogenesis inhibitor is present in an amount selected from the group consisting of from about 99.5% to about 0.001%, from about 95% to about 0.1%, and from about 90% to about 0.5%, by weight, based on the total combined weight of the angiogenesis inhibitor and at least one surface stabilizer, not including other excipients.

94. The composition of claim 87, wherein the at least one surface stabilizer is present in an amount selected from the group consisting of from about 0.5% to about 99.999%, from about 5.0% to about 99.9%, and from about 10% to about 99.5%, by weight, based on the total combined weight of the at least one angiogenesis inhibitor and at least one surface stabilizer, not including other excipients.

95. The composition of claim 87, comprising at least two surface stabilizers.

96. The composition of claim 87, wherein the surface stabilizer is selected from the group consisting of a non-ionic surface stabilizer, an anionic surface stabilizer, a cationic surface stabilizer, an ionic surface stabilizer, and a zwitterionic surface stabilizer.

97. The composition of claim 96, wherein at least one surface stabilizer is selected from the group consisting of hexyldecyl trimethyl ammonium chloride (CTAC), albumin, bovine serum albumin, human serum albumin, cetyl pyridinium chloride, gelatin, casein, phosphatides, dextran, glycerol, gum acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glycerol monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, polyethylene glycols, dodecyl trimethyl ammonium bromide, polyoxyethylene stearates, colloidal silicon dioxide, phosphates, sodium dodecylsulfate, carboxymethylcellulose calcium, hydroxypropyl celluloses, hydroxypropyl methylcellulose, carboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose, hydroxypropylmethyl-cellulose phthalate, noncrystalline cellulose, magnesium aluminum silicate, triethanolamine, polyvinyl alcohol, polyvinylpyrrolidone, 4-(1,1,3,3-tetramethylbutyl)-phenol polymer with ethylene oxide and formaldehyde, poloxamers;

poloxamines, a charged phospholipid, dioctylsulfosuccinate, dialkylesters of sodium sulfosuccinic acid, sodium lauryl sulfate, alkyl aryl polyether sulfonates, mixtures of sucrose stearate and sucrose distearate, C₁₈H₃₇CH₂C(O)N(CH₃)—

CH₂(CHOH)₄(CH₂OH)₂, p-isononylphenoxypoly-(glycidol), decanoyl-N-methylglucamide;

n-decyl β

-D-glucopyranoside;

n-decyl β

-D-maltopyranoside;

n-dodecyl β

-D-glucopyranoside;

n-dodecyl β

-D-maltoside;

heptanoyl-N-methylglucamide;

n-heptyl-β

-D-glucopyranoside;

n-heptyl β

-D-thioglucoside;

n-hexyl β

-D-glucopyranoside;

nonanoyl-N-methylglucamide;

n-noyl β

-D-glucopyranoside;

octanoyl-N-methylglucamide;

n-octyl-β

-D-glucopyranoside;

octyl β

-D-thioglucopyranoside;

lysozyme, PEG-phospholipid, PEG-cholesterol, PEG-cholesterol derivative, PEG-vitamin A, PEG-vitamin E, and random copolymers of vinyl acetate and vinyl pyrrolidone.

98. The composition of claim 87, wherein upon administration the composition redisperses such that the angiogenesis inhibitor particles have a particle size selected from the group consisting of less than about 2 microns, less than about 1900 nm, less than about 1800 nm, less than about 1700 nm, less than about 1600 nm, less than about 1500 nm, less than about 1400 nm, less than about 1300 nm, less than about 1200 nm, less than about 1100 nm, less than about 1000 nm, less than about 900 nm, less than about 800 mm, less than about 700 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 250 nm, less than about 200 nm, less than about 150 nm, less than about 100 nm, less than about 75 nm, and less than about 50 nm.

99. The composition of claim 87, wherein the composition does not produce significantly different absorption levels when administered under fed as compared to fasting conditions.

100. The composition of claim 87, wherein the difference in absorption of the angiogenesis inhibitor composition of the invention, when administered in the fed versus the fasted state, is selected from the group consisting of less than about 100%, less than about 90%, less than about 80%, less than about 70%, less than about 60%, less than about 50%, less than about 40%, less than about 35%, less than about 30%, less than about 25%, less than about 20%, less than about 15%, less than about 10%, less than about 5%, and less than about 3%.

101. The composition of claim 87, wherein the composition does not produce significantly different rates of absorption (T_max) when administered under fed as compared to fasting conditions.

102. The composition of claim 87, wherein the difference in the T_max for the angiogenesis inhibitor composition of the invention, when administered in the fed versus the fasted state, is less than about 100%, less than about 90%, less than about 80%, less than about 70%, less than about 60%, less than about 50%, less than about 40%, less than about 30%, less than about 20%, less than about 15%, less than about 10%, less than about 5%, and less than about 3%.

103. The composition of claim 87, wherein upon administration the T_max is less than that of a conventional non-nanoparticulate composition of the same angiogenesis inhibitor, administered at the same dosage.

104. The composition of claim 87, wherein in comparative pharmacokinetic testing with a non-nanoparticulate composition of the same angiogenesis inhibitor, administered at the same dosage, the composition exhibits a T_max selected from the group consisting of less than about 100%, less than about 90%, less than about 80%, less than about 70%, less than about 60%, less than about 50%, less than about 40%, less than about 30%, less than about 25%, less than about 20%, less than about 15%, and less than about 10% of the T_max exhibited by the non-nanoparticulate composition of the angiogenesis inhibitor.

105. The composition of claim 87, wherein following administration the composition has a T_max selected from the group consisting of less than about 2.5 hours, less than about 2.25 hours, less than about 2 hours, less than about 1.75 hours, less than about 1.5 hours, less than about 1.25 hours, less than about 1.0 hours, less than about 50 minutes, less than about 40 minutes, less than about 30 minutes, less than about 25 minutes, less than about 20 minutes, less than about 15 minutes, and less than about 10 minutes.

106. The composition of claim 87, wherein upon administration the C_max of the composition is greater than the C_max of a conventional non-nanoparticulate composition of the same angiogenesis inhibitor, administered at the same dosage.

107. The composition of claim 87, wherein in comparative pharmacokinetic testing with a non-nanoparticulate composition of the same angiogenesis inhibitor, administered at the same dosage, the nanoparticulate composition exhibits a C_max selected from the group consisting of greater than about 5%, greater than about 10%, greater than about 15%, greater than about 20%, greater than about 30%, greater than about 40%, greater than about 50%, greater than about 60%, greater than about 70%, greater than about 80%, greater than about 90%, greater than about 100%, greater than about 110%, greater than about 120%, greater than about 130%, greater than about 140%, and greater than about 150% than the C_max exhibited by the non-nanoparticulate composition of the angiogenesis inhibitor.

145. The composition of claim 87, wherein:

(a) the angiogenesis inhibitor is paclitaxel; and

(b) the surface stabilizer is not Tween 20, polyvinyl alcohol, hexyldecyl trimethyl ammonium chloride (CTAC), Aerosol OT, poloxamer 188 (also known as Pluronic F68), Tetronic 908, or Tween 80.

92. An angiogenesis inhibitor composition consisting of:

(a) particles of an angiogenesis inhibitor, wherein the angiogenesis inhibitor is paclitaxel or a salt thereof, having an effective average particle size of less than about 2000 nm;

(b) associated with the surface thereof at least one surface stabilizer, wherein the surface stabilizer is essentially free of intermolecular cross linkages; and

(c) one or more pharmaceutically acceptable excipients, carriers, or a combination thereof.

108. A method of making a solvent-free angiogenesis inhibitor composition comprising contacting particles of at least one angiogenesis inhibitor, wherein the angiogenesis inhibitor is paclitaxel or a salt thereof, with at least one surface stabilizer, wherein the surface stabilizer is essentially free of intermolecular cross linkages, for a time and under conditions sufficient to provide an angiogenesis inhibitor composition having an effective average particle size of less than about 2 microns.

109. The method of claim 108, wherein said contacting comprises grinding.

110. The method of claim 109, wherein said grinding comprises wet grinding.

111. The method of claim 108, wherein said contacting comprises homogenizing.

112. The method of claim 108, wherein said contacting comprises:

(a) dissolving the angiogenesis inhibitor particles in a solvent;

(b) adding the resulting angiogenesis inhibitor solution to a solution comprising at least one surface stabilizer; and

(c) precipitating the solubilized angiogenesis inhibitor having at least one surface stabilizer associated with the surface thereof by the addition thereto of a non-solvent.

113. The method of claim 108, wherein the angiogenesis inhibitor is selected from the group consisting of a crystalline phase, an amorphous phase, and a semi-crystalline phase.

114. The method of claim 108, wherein the effective average particle size of the nanoparticulate angiogenesis inhibitor particles is selected from the group consisting of less than about 1900 nm, less than about 1800 nm, less than about 1700 nm, less than about 1600 nm, less than about 1500 nm, less than about 1400 nm, less than about 1300 nm, less than about 1200 nm, less than about 1100 nm, less than about 1000 nm, less than about 900 nm, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 μ

m, less than about 400 μ

m, less than about 300 μ

m, less than about 250 nm, less than about 200 nm, less than about 100 nm, less than about 75 nm, and less than about 50 nm.

115. The method of claim 108, wherein the angiogenesis inhibitor is present in an amount selected from the group consisting of from about 99% to about 0.001%, from about 95% to about 0.5%, and from about 90% to about 0.5%, by weight, based on the total combined weight of the angiogenesis inhibitor and at least one surface stabilizer, not including other excipients.

116. The method of claim 108, wherein at least one surface stabilizer is present in an amount selected from the group consisting of from about 0.5% to about 99.999%, from about 5.0% to about 99.9%, and from about 10% to about 99.5%, by weight, based on the total combined dry weight of the angiogenesis inhibitor and at least one surface stabilizer, not including other excipients.

117. The method of claim 108, wherein the angiogenesis inhibitor particles are contacted with at least two surface stabilizers.

118. The method of claim 108, wherein the surface stabilizer is selected from the group consisting of a non-ionic surface stabilizer, an anionic surface stabilizer, a cationic surface stabilizer, an ionic surface stabilizer, and a zwitterionic surface stabilizer.

119. The method of claim 118, wherein at least one surface stabilizer is selected from the group consisting of hexyldecyl trimethyl ammonium chloride (CTAC), albumin, bovine serum albumin, human serum albumin, cetyl pyridinium chloride, gelatin, casein, phosphatides, dextran, glycerol, gum acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glycerol monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, polyethylene glycols, dodecyl trimethyl ammonium bromide, polyoxyethylene stearates, colloidal silicon dioxide, phosphates, sodium dodecylsulfate, carboxymethylcellulose calcium, hydroxypropyl celluloses, hydroxypropyl methylcellulose, carboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose, hydroxypropylmethyl-cellulose phthalate, noncrystalline cellulose, magnesium aluminum silicate, triethanolamine, polyvinyl alcohol, polyvinylpyrrolidone, 4-(1,1,3,3-tetramethylbutyl)-phenol polymer with ethylene oxide and formaldehyde, poloxamers;

poloxamines, a charged phospholipid, dioctylsulfosuccinate, dialkylesters of sodium sulfosuccinic acid, sodium lauryl sulfate, alkyl aryl polyether sulfonates, mixtures of sucrose stearate and sucrose distearate, C₁₈H₃₇CH₂C(O)N(CH₃)—

CH₂(CHOH)₄(CH₂OH)₂, p-isononylphenoxypoly-(glycidol), decanoyl-N-methylglucamide;

n-decyl β

-D-glucopyranoside;

n-decyl β

-D-maltopyranoside;

n-dodecyl β

-D-glucopyranoside;

n-dodecyl β

-D-maltoside;

heptanoyl-N-methylglucamide;

n-heptyl-β

-D-glucopyranoside;

n-heptyl β

-D-thioglucoside;

n-hexyl β

-D-glucopyranoside;

nonanoyl-N-methylglucamide;

n-noyl β

-D-glucopyranoside;

octanoyl-N-methylglucamide;

n-octyl-β

-D-glucopyranoside;

octyl β

-D-thioglucopyranoside;

lysozyme, PEG-phospholipid, PEG-cholesterol, PEG-cholesterol derivative, PEG-vitamin A, PEG-vitamin E, and random copolymers of vinyl acetate and vinyl pyrrolidone.

146. The method of claim 108, wherein:

(a) the angiogenesis inhibitor is paclitaxel; and

(b) the surface stabilizer is not Tween 20, polyvinyl alcohol, hexyldecyl trimethyl ammonium chloride (CTAC), Aerosol OT, poloxamer 188 (also known as Pluronic F68), Tetronic 908, or Tween 80.

120. A method of treating a subject in need with an angiogenesis inhibitor composition comprising administering to the subject an effective amount of a solvent-free angiogenesis inhibitor composition consisting of:

(a) particles of an angiogenesis inhibitor, wherein the angiogenesis inhibitor is paclitaxel or a salt thereof, having an effective average particle size of less than about 2000 nm; and

(b) associated with the surface thereof at least one surface stabilizer, wherein the surface stabilizer is essentially free of intermolecular cross linkages.

121. The method of claim 120, wherein the angiogenesis inhibitor is selected from the group consisting of a crystalline phase, an amorphous phase, and a semi-crystalline phase.

122. The method of claim 120, wherein the effective average particle size of the nanoparticulate angiogenesis inhibitor particles is selected from the group consisting of less than about 1900 nm, less than about 1800 nm, less than about 1700 nm, less than about 1600 nm, less than about 1500 nm, less than about 1400 nm, less than about 1300 nm, less than about 1200 nm, less than about 1100 nm, less than about 1000 nm, less than about 900 nm, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 250 nm, less than about 200 nm, less than about 100 nm, less than about 75 nm, and less than about 50 nm.

123. The method of claim 120, wherein the composition is formulated for an administration form selected from the group consisting of oral, pulmonary, rectal, opthalmic, colonic, parenteral, intracisternal, intravaginal, intraperitoneal, local, buccal, nasal, and topical administration.

124. The method of claim 120, wherein the composition is in a dosage form selected from the group consisting of liquid dispersions, gels, aerosols, ointments, creams, controlled release formulations, fast melt formulations, lyophilized formulations, tablets, capsules, delayed release formulations, extended release formulations, pulsatile release formulations, and mixed immediate release and controlled release formulations.

125. The method of claim 120, wherein the composition further comprises one or more pharmaceutically acceptable excipients, carriers, or a combination thereof.

126. The method of claim 120, wherein the angiogenesis inhibitor is present in an amount selected from the group consisting of from about 99% to about 0.001%, from about 95% to about 0.5%, and from about 90% to about 0.5%, by weight, based on the total combined weight of the angiogenesis inhibitor and at least one surface stabilizer, not including other excipients.

127. The method of claim 120, wherein at least one surface stabilizer is present in an amount selected from the group consisting of from about 0.5% to about 99.999%, from about 5.0% to about 99.9%, and from about 10% to about 99.5%, by weight, based on the total combined dry weight of angiogenesis inhibitor and at least one surface stabilizer, not including other excipients.

128. The method of claim 120, wherein the angiogenesis inhibitor composition comprises at least two surface stabilizers.

129. The method of claim 120, wherein the surface stabilizer is selected from the group consisting of a non-ionic surface stabilizer, an anionic surface stabilizer, a cationic surface stabilizer, an ionic surface stabilizer, and a zwitterionic surface stabilizer.

130. The method of claim 129, wherein the at least one surface stabilizer is selected from the group consisting of hexyldecyl trimethyl ammonium chloride (CTAC), albumin, bovine serum albumin, human serum albumin, cetyl pyridinium chloride, gelatin, casein, phosphatides, dextran, glycerol, gum acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glycerol monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, polyethylene glycols, dodecyl trimethyl ammonium bromide, polyoxyethylene stearates, colloidal silicon dioxide, phosphates, sodium dodecylsulfate, carboxymethylcellulose calcium, hydroxypropyl celluloses, hydroxypropyl methylcellulose, carboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose, hydroxypropylmethyl-cellulose phthalate, noncrystalline cellulose, magnesium aluminum silicate, triethanolamine, polyvinyl alcohol, polyvinylpyrrolidone, 4-(1,1,3,3-tetramethylbutyl)-phenol polymer with ethylene oxide and formaldehyde, poloxamers;

poloxamines, a charged phospholipid, dioctylsulfosuccinate, dialkylesters of sodium sulfosuccinic acid, sodium lauryl sulfate, alkyl aryl polyether sulfonates, mixtures of sucrose stearate and sucrose distearate, C₁₈H₃₇CH₂C(O)N(CH₃)—

CH₂(CHOH)₄(CH₂OH)₂, p-isononylphenoxypoly-(glycidol), decanoyl-N-methylglucamide;

n-decyl β

-D-glucopyranoside;

n-decyl β

-D-maltopyranoside;

n-dodecyl β

-D-glucopyranoside;

n-dodecyl β

-D-maltoside;

heptanoyl-N-methylglucamide;

n-heptyl-β

-D-glucopyranoside;

n-heptyl β

-D-thioglucoside;

n-hexyl β

-D-glucopyranoside;

nonanoyl-N-methylglucamide;

n-noyl β

-D-glucopyranoside;

octanoyl-N-methylglucamide;

n-octyl-β

-D-glucopyranoside;

octyl β

-D-thioglucopyranoside;

lysozyme, PEG-phospholipid, PEG-cholesterol, PEG-cholesterol derivative, PEG-vitamin A, PEG-vitamin E, and random copolymers of vinyl acetate and vinyl pyrrolidone.

131. The method of claim 120, wherein the composition does not produce significantly different absorption levels when administered under fed as compared to fasting conditions.

132. The method of claim 120, wherein the difference in absorption of the nanoparticulate angiogenesis inhibitor composition of the invention, when administered in the fed versus the fasted state, is selected from the group consisting of less than about 100%, less than about 90%, less than about 80%, less than about 70%, less than about 60%, less than about 50%, less than about 40%, less than about 35%, less than about 30%, less than about 25%, less than about 20%, less than about 15%, less than about 10%, less than about 5%, and less than about 3%.

133. The method of claim 120, wherein the composition does not produce significantly different rates of absorption (T_max) when administered under fed as compared to fasting conditions.

134. The method of claim 120, wherein the difference in the T_max for the nanoparticulate angiogenesis inhibitor composition of the invention, when administered in the fed versus the fasted state, is less than about 100%, less than about 90%, less than about 80%, less than about 70%, less than about 60%, less than about 50%, less than about 40%, less than about 30%, less than about 20%, less than about 15%, less than about 10%, less than about 5%, and less than about 3%.

135. The method of claim 120, wherein upon administration the T_max is less than that of a conventional non-nanoparticulate composition of the same angiogenesis inhibitor, administered at the same dosage.

136. The method of claim 120, wherein the nanoparticulate angiogenesis inhibitor composition exhibits a T_max, as compared to a non-nanoparticulate composition of the same angiogenesis inhibitor administered at the same dosage, selected from the group consisting of less than about 90%, less than about 80%, less than about 70%, less than about 60%, less than about 50%, less than about 40%, less than about 30%, less than about 25%, less than about 20%, less than about 15%, and less than about 10% of the T_max exhibited by the non-nanoparticulate composition of the angiogenesis inhibitor.

137. The method of claim 120, wherein upon administration the T_max of the composition is selected from the group consisting of less than about 2.5 hours, less than about 2.25 hours, less than about 2 hours, less than about 1.75 hours, less than about 1.5 hours, less than about 1.25 hours, less than about 1.0 hours, less than about 50 minutes, less than about 40 minutes, less than about 30 minutes, less than about 25 minutes, less than about 20 minutes, less than about 15 minutes, and less than about 10 minutes.

138. The method of claim 120, wherein upon administration the C_max of the composition is greater than the C_max of a conventional non-nanoparticulate composition of the same angiogenesis inhibitor, administered at the same dosage.

139. The method of claim 120, wherein the nanoparticulate angiogenesis inhibitor composition exhibits a C_max, as compared to a non-nanoparticulate composition of the same angiogenesis inhibitor administered at the same dosage, selected from the group consisting of greater than about 5%, greater than about 10%, greater than about 15%, greater than about 20%, greater than about 30%, greater than about 40%, greater than about 50%, greater than about 60%, greater than about 70%, greater than about 80%, greater than about 90%, greater than about 100%, greater than about 110%, greater than about 120%, greater than about 130%, greater than about 140%, and greater than about 150% than the C_max exhibited by the non-nanoparticulate composition of the angiogenesis inhibitor.

140. The method of claim 120, wherein the method is used to treat an condition where a selective angiogenesis inhibitor is indicated.

141. The method of claim 120, wherein the method is used to treat a mammalian disease characterized by undesirable angiogenesis.

142. The method of claim 120, wherein the method is used to treat or prevent tumor growth.

143. The method of claim 120, wherein the method is used to treat or prevent cancer growth.

144. The method of claim 120, wherein the subject is a human.

147. The method of claim 120, wherein:

(a) the angiogenesis inhibitor is paclitaxel; and

(b) the surface stabilizer is not Tween 20, polyvinyl alcohol, hexyldecyl trimethyl ammonium chloride (CTAC), Aerosol OT, poloxamer 188 (also known as Pluronic F68), Tetronic 908, or Tween 80.

148. A neoplastic inhibitor composition comprising:

(a) particles of a neoplastic inhibitor or a salt thereof having an effective average particle size of less than about 2000 nm; and

(b) associated with the surface thereof at least one non-crosslinked surface stabilizer.